Literature DB >> 19340432

Selective acquisition of IDH1 R132C mutations in astrocytomas associated with Li-Fraumeni syndrome.

Takuya Watanabe1, Anne Vital, Sumihito Nobusawa, Paul Kleihues, Hiroko Ohgaki.   

Abstract

Mutations of the IDH1 gene are frequent in gliomas, with R132H (CGT-->CAT) being the most common (>85%). In astrocytomas, IDH1 mutations are typically co-present with, or precede, TP53 mutations. We assessed IDH1 mutations in brain tumors diagnosed in patients from three families with Li-Fraumeni syndrome. We identified IDH1 mutations in five astrocytomas that developed in carriers of a TP53 germline mutation. Without exception, all were R132C (CGT-->TGT), which in sporadic astrocytomas accounts for <5% of IDH1 mutations. This remarkably selective occurrence of R132C mutations may reflect differences in the sequence of genetic events, with a preference for R132C mutations in astrocytes or precursor cells that already carry a germline TP53 mutation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19340432     DOI: 10.1007/s00401-009-0528-x

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  24 in total

1.  Predicting IDH mutation status in grade II gliomas using amide proton transfer-weighted (APTw) MRI.

Authors:  Shanshan Jiang; Tianyu Zou; Charles G Eberhart; Maria A V Villalobos; Hye-Young Heo; Yi Zhang; Yu Wang; Xianlong Wang; Hao Yu; Yongxing Du; Peter C M van Zijl; Zhibo Wen; Jinyuan Zhou
Journal:  Magn Reson Med       Date:  2017-07-16       Impact factor: 4.668

Review 2.  Update on molecular findings, management and outcome in low-grade gliomas.

Authors:  T David Bourne; David Schiff
Journal:  Nat Rev Neurol       Date:  2010-11-02       Impact factor: 42.937

3.  Isocitrate dehydrogenase mutations suppress STAT1 and CD8+ T cell accumulation in gliomas.

Authors:  Gary Kohanbash; Diego A Carrera; Shruti Shrivastav; Brian J Ahn; Naznin Jahan; Tali Mazor; Zinal S Chheda; Kira M Downey; Payal B Watchmaker; Casey Beppler; Rolf Warta; Nduka A Amankulor; Christel Herold-Mende; Joseph F Costello; Hideho Okada
Journal:  J Clin Invest       Date:  2017-03-20       Impact factor: 14.808

Review 4.  Brain Cancers in Genetic Syndromes.

Authors:  Edina Komlodi-Pasztor; Jaishri O Blakeley
Journal:  Curr Neurol Neurosci Rep       Date:  2021-11-22       Impact factor: 5.081

5.  The prognostic IDH1( R132 ) mutation is associated with reduced NADP+-dependent IDH activity in glioblastoma.

Authors:  Fonnet E Bleeker; Nadia A Atai; Simona Lamba; Ard Jonker; Denise Rijkeboer; Klazien S Bosch; Wikky Tigchelaar; Dirk Troost; W Peter Vandertop; Alberto Bardelli; Cornelis J F Van Noorden
Journal:  Acta Neuropathol       Date:  2010-02-04       Impact factor: 17.088

Review 6.  Molecular diagnostics of gliomas: state of the art.

Authors:  Markus J Riemenschneider; Judith W M Jeuken; Pieter Wesseling; Guido Reifenberger
Journal:  Acta Neuropathol       Date:  2010-08-17       Impact factor: 17.088

Review 7.  IDH mutations in human glioma.

Authors:  Won Kim; Linda M Liau
Journal:  Neurosurg Clin N Am       Date:  2012-05-31       Impact factor: 2.509

8.  Genomic analysis of the origins and evolution of multicentric diffuse lower-grade gliomas.

Authors:  Josie Hayes; Yao Yu; Llewellyn E Jalbert; Tali Mazor; Lindsey E Jones; Matthew D Wood; Kyle M Walsh; Henrik Bengtsson; Chibo Hong; Stefan Oberndorfer; Thomas Roetzer; Ivan V Smirnov; Jennifer L Clarke; Manish K Aghi; Susan M Chang; Sarah J Nelson; Adelheid Woehrer; Joanna J Phillips; David A Solomon; Joseph F Costello
Journal:  Neuro Oncol       Date:  2018-04-09       Impact factor: 12.300

Review 9.  Isocitrate dehydrogenase 1 and 2 mutations in cancer: alterations at a crossroads of cellular metabolism.

Authors:  Zachary J Reitman; Hai Yan
Journal:  J Natl Cancer Inst       Date:  2010-05-31       Impact factor: 11.816

10.  GNG5 is a novel oncogene associated with cell migration, proliferation, and poor prognosis in glioma.

Authors:  Wang Zhang; Zhendong Liu; Binchao Liu; Miaomiao Jiang; Shi Yan; Xian Han; Hong Shen; Meng Na; Yanbiao Wang; Zhishuai Ren; Binfeng Liu; Zhenfeng Jiang; Yanzheng Gao; Zhiguo Lin
Journal:  Cancer Cell Int       Date:  2021-06-07       Impact factor: 5.722

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.